Share Price and Basic Stock Data
Last Updated: February 3, 2026, 2:24 am
| PEG Ratio | -2.67 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
IOL Chemicals & Pharmaceuticals Ltd operates within the pharmaceutical sector, focusing on the manufacture of active pharmaceutical ingredients and intermediates. The company reported sales of ₹2,217 Cr for the fiscal year ending March 2023, a marginal increase from ₹2,184 Cr in the previous year. However, sales for the trailing twelve months (TTM) stood at ₹2,170 Cr, indicating a slight dip in revenue generation. The quarterly sales figures reveal fluctuations, with the highest sales recorded in March 2023 at ₹587 Cr, followed by a decline to ₹520 Cr in December 2023. This inconsistency in sales trends may reflect the competitive pressures within the pharmaceutical industry, which typically sees varying demand cycles. The company’s operational efficiency, reflected in its operating profit margin (OPM), stood at 10% for the fiscal year 2025, showing a decline from 12% in the previous fiscal year. The overall revenue growth trajectory remains critical for sustaining market position and investor sentiment in a sector characterized by rapid innovation and regulatory scrutiny.
Profitability and Efficiency Metrics
IOL Chemicals & Pharmaceuticals has demonstrated varied profitability metrics over recent financial periods. The net profit for the fiscal year ending March 2023 was reported at ₹140 Cr, a decrease from ₹166 Cr in the prior year, leading to a net profit margin of 6.3%. The company’s operating profit also faced challenges, with an operating profit of ₹202 Cr and an operating profit margin of 10% for the fiscal year ending March 2025, down from 12% in the previous year. Efficiency ratios highlight a cash conversion cycle (CCC) of 73 days, which, while manageable, reflects the company’s operational liquidity management challenges compared to industry peers who often achieve lower CCC figures. Additionally, the return on equity (ROE) stood at 6.13%, indicating a conservative return on shareholder investment. The interest coverage ratio (ICR) was recorded at 15.22x, demonstrating strong ability to service debt, yet the declining profitability metrics raise concerns about sustaining future earnings growth.
Balance Sheet Strength and Financial Ratios
The balance sheet of IOL Chemicals & Pharmaceuticals reflects a stable financial position with total assets amounting to ₹2,382 Cr as of March 2025. The company reported reserves of ₹1,692 Cr, indicating a solid equity base for future investments. Total borrowings were relatively low at ₹159 Cr, resulting in a debt-to-equity ratio of 0.06, which is significantly lower than industry norms, highlighting a conservative approach to leveraging. The current ratio stood at 1.89, suggesting adequate short-term liquidity, while the quick ratio of 1.30 reinforces the company’s ability to meet immediate liabilities. However, the return on capital employed (ROCE) has shown a declining trend, standing at 9% for March 2025, compared to 11.74% in the previous year. This decline in ROCE raises questions about the effective utilization of capital in generating profits. Overall, while the balance sheet remains robust, the declining efficiency ratios warrant scrutiny.
Shareholding Pattern and Investor Confidence
The shareholding pattern of IOL Chemicals & Pharmaceuticals reveals significant insights into investor confidence and corporate governance. As of September 2025, promoters held a substantial 52.62% stake, reflecting strong management control. However, foreign institutional investors (FIIs) have shown a decreasing trend, with their stake declining to 2.25%, down from 3.54% in June 2023. Domestic institutional investors (DIIs) remain minimal at 0.05%, which could indicate a lack of institutional interest in the stock, potentially affecting liquidity and market perception. The public holds 45.10% of shares, with the total number of shareholders recorded at 1,36,129, suggesting a broad retail investor base. The increasing promoter holding coupled with declining institutional participation may signal a need for improved communication and engagement strategies to attract institutional investment, which is critical for enhancing market credibility and share price stability.
Outlook, Risks, and Final Insight
The outlook for IOL Chemicals & Pharmaceuticals is shaped by both opportunities and risks inherent in the pharmaceutical sector. Strengths include a solid financial foundation with low leverage and a significant equity reserve, which positions the company well for strategic investments and future growth. However, profitability pressures, as evidenced by declining net profits and operating margins, pose significant challenges. Additionally, the company faces competitive risks from both domestic and international players, which could further impact revenue stability. Regulatory changes and market dynamics in the pharmaceutical industry may also influence operational performance. To enhance investor confidence and market position, IOL Chemicals must focus on improving operational efficiency, sustaining revenue growth, and potentially increasing institutional investor engagement. A strategic pivot towards innovation and market diversification may provide pathways for recovery and growth in a highly competitive landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 122 Cr. | 97.0 | 193/84.3 | 27.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,473 Cr. | 319 | 479/192 | 71.9 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.9 Cr. | 44.3 | 82.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 73.2 Cr. | 50.0 | 50.0/17.0 | 174 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,464.08 Cr | 1,084.45 | 46.05 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
All Competitor Stocks of IOL Chemicals & Pharmaceuticals Ltd
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 541 | 523 | 587 | 563 | 545 | 520 | 504 | 502 | 526 | 523 | 528 | 552 | 568 |
| Expenses | 510 | 480 | 491 | 490 | 481 | 476 | 454 | 452 | 484 | 476 | 465 | 490 | 510 |
| Operating Profit | 32 | 43 | 96 | 73 | 64 | 44 | 50 | 51 | 42 | 47 | 63 | 62 | 57 |
| OPM % | 6% | 8% | 16% | 13% | 12% | 9% | 10% | 10% | 8% | 9% | 12% | 11% | 10% |
| Other Income | 5 | 7 | 9 | 7 | 7 | 8 | 8 | 7 | 6 | 4 | 5 | 7 | 7 |
| Interest | 4 | 5 | 5 | 4 | 4 | 4 | 3 | 2 | 4 | 4 | 4 | 4 | 3 |
| Depreciation | 11 | 12 | 12 | 14 | 16 | 16 | 16 | 17 | 18 | 19 | 19 | 20 | 20 |
| Profit before tax | 22 | 33 | 88 | 62 | 51 | 32 | 38 | 39 | 26 | 28 | 45 | 46 | 41 |
| Tax % | 28% | 27% | 25% | 25% | 26% | 28% | 25% | 24% | 26% | 26% | 30% | 25% | 26% |
| Net Profit | 16 | 24 | 65 | 46 | 38 | 23 | 28 | 30 | 19 | 21 | 32 | 34 | 30 |
| EPS in Rs | 0.53 | 0.82 | 2.22 | 1.57 | 1.29 | 0.79 | 0.96 | 1.01 | 0.65 | 0.70 | 1.08 | 1.16 | 1.02 |
Last Updated: January 1, 2026, 6:16 am
Below is a detailed analysis of the quarterly data for IOL Chemicals & Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 568.00 Cr.. The value appears strong and on an upward trend. It has increased from 552.00 Cr. (Jun 2025) to 568.00 Cr., marking an increase of 16.00 Cr..
- For Expenses, as of Sep 2025, the value is 510.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 490.00 Cr. (Jun 2025) to 510.00 Cr., marking an increase of 20.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 57.00 Cr.. The value appears to be declining and may need further review. It has decreased from 62.00 Cr. (Jun 2025) to 57.00 Cr., marking a decrease of 5.00 Cr..
- For OPM %, as of Sep 2025, the value is 10.00%. The value appears to be declining and may need further review. It has decreased from 11.00% (Jun 2025) to 10.00%, marking a decrease of 1.00%.
- For Other Income, as of Sep 2025, the value is 7.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 7.00 Cr..
- For Interest, as of Sep 2025, the value is 3.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.00 Cr. (Jun 2025) to 3.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 20.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 20.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 41.00 Cr.. The value appears to be declining and may need further review. It has decreased from 46.00 Cr. (Jun 2025) to 41.00 Cr., marking a decrease of 5.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Jun 2025) to 26.00%, marking an increase of 1.00%.
- For Net Profit, as of Sep 2025, the value is 30.00 Cr.. The value appears to be declining and may need further review. It has decreased from 34.00 Cr. (Jun 2025) to 30.00 Cr., marking a decrease of 4.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 1.02. The value appears to be declining and may need further review. It has decreased from 1.16 (Jun 2025) to 1.02, marking a decrease of 0.14.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:10 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 564 | 385 | 580 | 711 | 983 | 1,685 | 1,894 | 1,967 | 2,184 | 2,217 | 2,133 | 2,079 | 2,170 |
| Expenses | 468 | 373 | 529 | 608 | 863 | 1,276 | 1,321 | 1,375 | 1,927 | 1,990 | 1,901 | 1,877 | 1,941 |
| Operating Profit | 96 | 11 | 51 | 102 | 120 | 410 | 574 | 592 | 257 | 227 | 232 | 202 | 229 |
| OPM % | 17% | 3% | 9% | 14% | 12% | 24% | 30% | 30% | 12% | 10% | 11% | 10% | 11% |
| Other Income | 1 | 1 | 1 | 1 | 6 | 10 | 16 | 24 | 17 | 25 | 30 | 22 | 23 |
| Interest | 60 | 59 | 61 | 68 | 64 | 51 | 21 | 6 | 8 | 16 | 16 | 15 | 16 |
| Depreciation | 32 | 29 | 30 | 30 | 30 | 32 | 36 | 39 | 43 | 46 | 63 | 72 | 77 |
| Profit before tax | 5 | -75 | -39 | 6 | 31 | 336 | 533 | 571 | 223 | 189 | 183 | 138 | 159 |
| Tax % | 35% | -12% | 4% | 21% | 12% | 30% | 32% | 22% | 26% | 26% | 26% | 27% | |
| Net Profit | 3 | -67 | -40 | 5 | 28 | 237 | 361 | 445 | 166 | 140 | 135 | 101 | 116 |
| EPS in Rs | 0.23 | -2.80 | -1.42 | 0.17 | 0.99 | 8.32 | 12.70 | 15.15 | 5.64 | 4.77 | 4.61 | 3.44 | 3.96 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | 5% | 8% | 14% | 17% | 22% | 23% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -2333.33% | 40.30% | 112.50% | 460.00% | 746.43% | 52.32% | 23.27% | -62.70% | -15.66% | -3.57% | -25.19% |
| Change in YoY Net Profit Growth (%) | 0.00% | 2373.63% | 72.20% | 347.50% | 286.43% | -694.11% | -29.05% | -85.97% | 47.03% | 12.09% | -21.61% |
IOL Chemicals & Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 2% |
| 3 Years: | -2% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | -22% |
| 3 Years: | -17% |
| TTM: | -11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | -8% |
| 3 Years: | 10% |
| 1 Year: | 4% |
| Return on Equity | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 14% |
| 3 Years: | 8% |
| Last Year: | 6% |
Last Updated: September 5, 2025, 7:50 am
Balance Sheet
Last Updated: December 10, 2025, 2:52 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 29 | 48 | 56 | 56 | 56 | 57 | 57 | 59 | 59 | 59 | 59 | 59 | 59 |
| Reserves | 160 | 160 | 129 | 132 | 160 | 417 | 757 | 1,202 | 1,332 | 1,448 | 1,553 | 1,629 | 1,692 |
| Borrowings | 377 | 400 | 453 | 447 | 422 | 284 | 59 | 3 | 44 | 80 | 33 | 117 | 159 |
| Other Liabilities | 175 | 94 | 135 | 182 | 214 | 184 | 297 | 347 | 526 | 434 | 600 | 577 | 503 |
| Total Liabilities | 741 | 702 | 772 | 817 | 852 | 942 | 1,170 | 1,610 | 1,960 | 2,021 | 2,244 | 2,382 | 2,413 |
| Fixed Assets | 411 | 403 | 400 | 374 | 406 | 412 | 469 | 512 | 561 | 751 | 933 | 1,170 | 1,142 |
| CWIP | 33 | 4 | 4 | 21 | 7 | 27 | 19 | 48 | 105 | 90 | 101 | 22 | 64 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 20 | 21 | 21 | 21 |
| Other Assets | 297 | 295 | 369 | 422 | 439 | 503 | 682 | 1,048 | 1,292 | 1,159 | 1,190 | 1,168 | 1,185 |
| Total Assets | 741 | 702 | 772 | 817 | 852 | 942 | 1,170 | 1,610 | 1,960 | 2,021 | 2,244 | 2,382 | 2,413 |
Below is a detailed analysis of the balance sheet data for IOL Chemicals & Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 59.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 59.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,692.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,629.00 Cr. (Mar 2025) to 1,692.00 Cr., marking an increase of 63.00 Cr..
- For Borrowings, as of Sep 2025, the value is 159.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 117.00 Cr. (Mar 2025) to 159.00 Cr., marking an increase of 42.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 503.00 Cr.. The value appears to be improving (decreasing). It has decreased from 577.00 Cr. (Mar 2025) to 503.00 Cr., marking a decrease of 74.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,413.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,382.00 Cr. (Mar 2025) to 2,413.00 Cr., marking an increase of 31.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,142.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,170.00 Cr. (Mar 2025) to 1,142.00 Cr., marking a decrease of 28.00 Cr..
- For CWIP, as of Sep 2025, the value is 64.00 Cr.. The value appears strong and on an upward trend. It has increased from 22.00 Cr. (Mar 2025) to 64.00 Cr., marking an increase of 42.00 Cr..
- For Investments, as of Sep 2025, the value is 21.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 21.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,185.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,168.00 Cr. (Mar 2025) to 1,185.00 Cr., marking an increase of 17.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,413.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,382.00 Cr. (Mar 2025) to 2,413.00 Cr., marking an increase of 31.00 Cr..
Notably, the Reserves (1,692.00 Cr.) exceed the Borrowings (159.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -281.00 | -389.00 | -402.00 | -345.00 | -302.00 | 126.00 | 515.00 | 589.00 | 213.00 | 147.00 | 199.00 | 85.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 32 | 31 | 55 | 58 | 54 | 43 | 52 | 56 | 79 | 83 | 81 | 90 |
| Inventory Days | 190 | 279 | 201 | 201 | 109 | 66 | 64 | 98 | 95 | 77 | 111 | 95 |
| Days Payable | 119 | 92 | 102 | 115 | 83 | 42 | 62 | 79 | 95 | 74 | 123 | 112 |
| Cash Conversion Cycle | 103 | 218 | 154 | 144 | 80 | 67 | 55 | 74 | 79 | 86 | 69 | 73 |
| Working Capital Days | -5 | 59 | 39 | 36 | 23 | 43 | 46 | 66 | 71 | 72 | 71 | 58 |
| ROCE % | 11% | -3% | 4% | 12% | 15% | 56% | 68% | 54% | 18% | 14% | 12% | 9% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal Nifty Microcap 250 Index Fund | 25,342 | 0.2 | 1.15 | 25,342 | 2025-04-22 17:25:30 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 243 | 0.12 | 0.01 | 243 | 2025-04-22 17:25:30 | 0% |
| Groww Nifty Total Market Index Fund | 65 | 0.01 | 0 | 65 | 2025-04-22 17:25:30 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|
| FaceValue | 2.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 3.44 | 22.90 | 23.70 | 28.56 |
| Diluted EPS (Rs.) | 3.44 | 22.90 | 23.70 | 28.56 |
| Cash EPS (Rs.) | 5.90 | 33.61 | 31.56 | 35.93 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 57.49 | 274.49 | 256.81 | 237.15 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 57.49 | 274.49 | 256.81 | 237.15 |
| Revenue From Operations / Share (Rs.) | 70.83 | 363.27 | 377.64 | 372.00 |
| PBDIT / Share (Rs.) | 7.65 | 44.40 | 42.80 | 49.45 |
| PBIT / Share (Rs.) | 5.20 | 33.68 | 34.94 | 42.08 |
| PBT / Share (Rs.) | 4.70 | 30.94 | 32.13 | 38.30 |
| Net Profit / Share (Rs.) | 3.44 | 22.90 | 23.70 | 28.56 |
| NP After MI And SOA / Share (Rs.) | 3.44 | 22.90 | 23.70 | 28.56 |
| PBDIT Margin (%) | 10.80 | 12.22 | 11.33 | 13.29 |
| PBIT Margin (%) | 7.34 | 9.27 | 9.25 | 11.31 |
| PBT Margin (%) | 6.63 | 8.51 | 8.50 | 10.29 |
| Net Profit Margin (%) | 4.86 | 6.30 | 6.27 | 7.67 |
| NP After MI And SOA Margin (%) | 4.86 | 6.30 | 6.27 | 7.67 |
| Return on Networth / Equity (%) | 5.98 | 8.34 | 9.22 | 12.04 |
| Return on Capital Employeed (%) | 8.61 | 11.74 | 13.09 | 17.05 |
| Return On Assets (%) | 4.24 | 5.98 | 6.88 | 8.54 |
| Total Debt / Equity (X) | 0.06 | 0.00 | 0.05 | 0.03 |
| Asset Turnover Ratio (%) | 0.89 | 0.99 | 1.11 | 0.00 |
| Current Ratio (X) | 1.89 | 2.00 | 2.02 | 2.11 |
| Quick Ratio (X) | 1.30 | 1.24 | 1.30 | 1.31 |
| Inventory Turnover Ratio (X) | 5.29 | 3.82 | 4.18 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 23.23 | 21.83 | 16.88 | 21.00 |
| Dividend Payout Ratio (CP) (%) | 13.56 | 14.87 | 12.68 | 16.69 |
| Earning Retention Ratio (%) | 76.77 | 78.17 | 83.12 | 79.00 |
| Cash Earning Retention Ratio (%) | 86.44 | 85.13 | 87.32 | 83.31 |
| Interest Coverage Ratio (X) | 15.22 | 16.19 | 15.26 | 35.02 |
| Interest Coverage Ratio (Post Tax) (X) | 7.85 | 9.35 | 9.45 | 22.91 |
| Enterprise Value (Cr.) | 1705.42 | 1979.48 | 1718.71 | 1979.92 |
| EV / Net Operating Revenue (X) | 0.82 | 0.92 | 0.77 | 0.90 |
| EV / EBITDA (X) | 7.59 | 7.59 | 6.84 | 6.82 |
| MarketCap / Net Operating Revenue (X) | 0.86 | 0.99 | 0.74 | 0.95 |
| Retention Ratios (%) | 76.76 | 78.16 | 83.11 | 78.99 |
| Price / BV (X) | 1.06 | 1.32 | 1.10 | 1.49 |
| Price / Net Operating Revenue (X) | 0.86 | 0.99 | 0.74 | 0.95 |
| EarningsYield | 0.05 | 0.06 | 0.08 | 0.08 |
After reviewing the key financial ratios for IOL Chemicals & Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 10.00 (Mar 24) to 2.00, marking a decrease of 8.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 3.44. This value is below the healthy minimum of 5. It has decreased from 22.90 (Mar 24) to 3.44, marking a decrease of 19.46.
- For Diluted EPS (Rs.), as of Mar 25, the value is 3.44. This value is below the healthy minimum of 5. It has decreased from 22.90 (Mar 24) to 3.44, marking a decrease of 19.46.
- For Cash EPS (Rs.), as of Mar 25, the value is 5.90. This value is within the healthy range. It has decreased from 33.61 (Mar 24) to 5.90, marking a decrease of 27.71.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 57.49. It has decreased from 274.49 (Mar 24) to 57.49, marking a decrease of 217.00.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 57.49. It has decreased from 274.49 (Mar 24) to 57.49, marking a decrease of 217.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 70.83. It has decreased from 363.27 (Mar 24) to 70.83, marking a decrease of 292.44.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 7.65. This value is within the healthy range. It has decreased from 44.40 (Mar 24) to 7.65, marking a decrease of 36.75.
- For PBIT / Share (Rs.), as of Mar 25, the value is 5.20. This value is within the healthy range. It has decreased from 33.68 (Mar 24) to 5.20, marking a decrease of 28.48.
- For PBT / Share (Rs.), as of Mar 25, the value is 4.70. This value is within the healthy range. It has decreased from 30.94 (Mar 24) to 4.70, marking a decrease of 26.24.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 3.44. This value is within the healthy range. It has decreased from 22.90 (Mar 24) to 3.44, marking a decrease of 19.46.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 3.44. This value is within the healthy range. It has decreased from 22.90 (Mar 24) to 3.44, marking a decrease of 19.46.
- For PBDIT Margin (%), as of Mar 25, the value is 10.80. This value is within the healthy range. It has decreased from 12.22 (Mar 24) to 10.80, marking a decrease of 1.42.
- For PBIT Margin (%), as of Mar 25, the value is 7.34. This value is below the healthy minimum of 10. It has decreased from 9.27 (Mar 24) to 7.34, marking a decrease of 1.93.
- For PBT Margin (%), as of Mar 25, the value is 6.63. This value is below the healthy minimum of 10. It has decreased from 8.51 (Mar 24) to 6.63, marking a decrease of 1.88.
- For Net Profit Margin (%), as of Mar 25, the value is 4.86. This value is below the healthy minimum of 5. It has decreased from 6.30 (Mar 24) to 4.86, marking a decrease of 1.44.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 4.86. This value is below the healthy minimum of 8. It has decreased from 6.30 (Mar 24) to 4.86, marking a decrease of 1.44.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.98. This value is below the healthy minimum of 15. It has decreased from 8.34 (Mar 24) to 5.98, marking a decrease of 2.36.
- For Return on Capital Employeed (%), as of Mar 25, the value is 8.61. This value is below the healthy minimum of 10. It has decreased from 11.74 (Mar 24) to 8.61, marking a decrease of 3.13.
- For Return On Assets (%), as of Mar 25, the value is 4.24. This value is below the healthy minimum of 5. It has decreased from 5.98 (Mar 24) to 4.24, marking a decrease of 1.74.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.06, marking an increase of 0.06.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.89. It has decreased from 0.99 (Mar 24) to 0.89, marking a decrease of 0.10.
- For Current Ratio (X), as of Mar 25, the value is 1.89. This value is within the healthy range. It has decreased from 2.00 (Mar 24) to 1.89, marking a decrease of 0.11.
- For Quick Ratio (X), as of Mar 25, the value is 1.30. This value is within the healthy range. It has increased from 1.24 (Mar 24) to 1.30, marking an increase of 0.06.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.29. This value is within the healthy range. It has increased from 3.82 (Mar 24) to 5.29, marking an increase of 1.47.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 23.23. This value is within the healthy range. It has increased from 21.83 (Mar 24) to 23.23, marking an increase of 1.40.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 13.56. This value is below the healthy minimum of 20. It has decreased from 14.87 (Mar 24) to 13.56, marking a decrease of 1.31.
- For Earning Retention Ratio (%), as of Mar 25, the value is 76.77. This value exceeds the healthy maximum of 70. It has decreased from 78.17 (Mar 24) to 76.77, marking a decrease of 1.40.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 86.44. This value exceeds the healthy maximum of 70. It has increased from 85.13 (Mar 24) to 86.44, marking an increase of 1.31.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 15.22. This value is within the healthy range. It has decreased from 16.19 (Mar 24) to 15.22, marking a decrease of 0.97.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.85. This value is within the healthy range. It has decreased from 9.35 (Mar 24) to 7.85, marking a decrease of 1.50.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,705.42. It has decreased from 1,979.48 (Mar 24) to 1,705.42, marking a decrease of 274.06.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 1. It has decreased from 0.92 (Mar 24) to 0.82, marking a decrease of 0.10.
- For EV / EBITDA (X), as of Mar 25, the value is 7.59. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 7.59.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 1. It has decreased from 0.99 (Mar 24) to 0.86, marking a decrease of 0.13.
- For Retention Ratios (%), as of Mar 25, the value is 76.76. This value exceeds the healthy maximum of 70. It has decreased from 78.16 (Mar 24) to 76.76, marking a decrease of 1.40.
- For Price / BV (X), as of Mar 25, the value is 1.06. This value is within the healthy range. It has decreased from 1.32 (Mar 24) to 1.06, marking a decrease of 0.26.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 1. It has decreased from 0.99 (Mar 24) to 0.86, marking a decrease of 0.13.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 24) to 0.05, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in IOL Chemicals & Pharmaceuticals Ltd:
- Net Profit Margin: 4.86%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 8.61% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.98% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.85
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.3
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 18.2 (Industry average Stock P/E: 46.05)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 4.86%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Village & Post Office Handiaya, Barnala Punjab 148107 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rajender Mohan Malla | Chairman & Ind.Director |
| Mr. Varinder Gupta | Managing Director |
| Mr. Vikas Gupta | Joint Managing Director |
| Mr. Abhiraj Gupta | Executive Director |
| Mr. Kushal Kumar Rana | Director - Works |
| Mr. Harpal Singh | Independent Director |
| Mr. Sharad Tyagi | Independent Director |
| Mr. Rajni Jha | Independent Director |
FAQ
What is the intrinsic value of IOL Chemicals & Pharmaceuticals Ltd?
IOL Chemicals & Pharmaceuticals Ltd's intrinsic value (as of 05 February 2026) is ₹50.20 which is 30.37% lower the current market price of ₹72.10, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹2,113 Cr. market cap, FY2025-2026 high/low of ₹127/57.5, reserves of ₹1,692 Cr, and liabilities of ₹2,413 Cr.
What is the Market Cap of IOL Chemicals & Pharmaceuticals Ltd?
The Market Cap of IOL Chemicals & Pharmaceuticals Ltd is 2,113 Cr..
What is the current Stock Price of IOL Chemicals & Pharmaceuticals Ltd as on 05 February 2026?
The current stock price of IOL Chemicals & Pharmaceuticals Ltd as on 05 February 2026 is ₹72.1.
What is the High / Low of IOL Chemicals & Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of IOL Chemicals & Pharmaceuticals Ltd stocks is ₹127/57.5.
What is the Stock P/E of IOL Chemicals & Pharmaceuticals Ltd?
The Stock P/E of IOL Chemicals & Pharmaceuticals Ltd is 18.2.
What is the Book Value of IOL Chemicals & Pharmaceuticals Ltd?
The Book Value of IOL Chemicals & Pharmaceuticals Ltd is 59.7.
What is the Dividend Yield of IOL Chemicals & Pharmaceuticals Ltd?
The Dividend Yield of IOL Chemicals & Pharmaceuticals Ltd is 1.11 %.
What is the ROCE of IOL Chemicals & Pharmaceuticals Ltd?
The ROCE of IOL Chemicals & Pharmaceuticals Ltd is 8.86 %.
What is the ROE of IOL Chemicals & Pharmaceuticals Ltd?
The ROE of IOL Chemicals & Pharmaceuticals Ltd is 6.13 %.
What is the Face Value of IOL Chemicals & Pharmaceuticals Ltd?
The Face Value of IOL Chemicals & Pharmaceuticals Ltd is 2.00.